Treatment News : HIV Drug Shuts Down Precancerous HPV-Infected Cells

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » May 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


May 3, 2011

HIV Drug Shuts Down Precancerous HPV-Infected Cells

The antiretroviral (ARV) drug lopinavir (found in Kaletra) is able to kill cervical cells infected with the human papillomavirus (HPV)—cells that can go on to become cancerous—according to a study published online May 5 in the journal Antiviral Therapy.

HPV is one of the most widely spread viruses in the world. Transmitted through sexual contact, some strains cause genital warts, while others can cause cells to mutate and become cancerous, thereby leading to cervical cancer, anal cancer, penile cancer and cancers of the head and neck.

Though there is now a vaccine against several strains of HPV, it can only prevent HPV. It doesn’t protect someone already infected from developing cancer. Also, HIV-positive women have much higher rates of cervical cancer than women without HIV, and cervical cancer is a leading cause of death in both HIV-positive and HIV-negative women in resource poor countries.

In announcing the new findings, the study’s senior author—Ian Hampson, PhD, from the University of Manchester in England—noted that he and his colleagues were the first to document that lopinavir could be toxic to HPV, as reported in a fall 2006 issue of Antiviral Therapy.

More recently, Hampson and his team looked specifically at whether lopinavir’s toxic effect on HPV-infected cells in the cervix is limited to just those cells, while leaving healthy uninfected cells alone. They found that it did just that.

The concentration of lopinavir needed to kill the HPV-infected cells is far too high to take it orally as a capsule, so it will need to be developed as a cream that can be applied directly to the cervix or as an inserted device, called a pessary, that can deliver the drug.

“Our results suggest that for this drug to work against HPV it would be necessary to treat virus-infected cells of the cervix with roughly 10–15 times the concentration that is normally found in HIV-infected patients taking lopinavir as tablets,” Hampson said.  

Hampson doesn’t mention whether lopinavir could be used for other types of HPV-associated cancers, but the cellular mechanisms whereby HIV leads cervical cells to become cancerous are very similar to how cells in the anus become cancerous.

“Lopinavir is obviously safe for people to take as tablets or liquid, but our latest findings provide very strong evidence to support a clinical trial using topical application of this drug to treat HPV infections of the cervix,” Hampson concludes.

Search: human papillomavirus (HPV), cervical cancer, anal cancer, penile cancer, Kaletra, lopinavir, Ian Hampson, University of Manchester

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.